3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1
4
Phase 4
1
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
4
Neoplasms
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Sepsis
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hematologic Diseases
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioblastoma
1
Fever
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
60
Vincristine
57
Doxorubicin
54
Rituximab
48
Prednisone
44
Etoposide
35
Radiotherapy
34
Cytarabine
26
Filgrastim
22
Methotrexate
21
Bleomycin
21
Dexamethasone
18
Peripheral Blood Stem Cell Transplantation
14
Carmustine
14
Vinblastine
13
Prednisolone
13
VAP-cyclo protocol
12
Melphalan
12
Mitoxantrone
11
Mercaptopurine
10
Leucovorin
10
Dacarbazine
9
Ifosfamide
8
Granulocyte Colony-Stimulating Factor
8
Procarbazine
7
Methylprednisolone
7
Lenalidomide
7
Gemcitabine
7
Daunorubicin
7
Cisplatin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT00091676
2012-02-03
BiovaxID
Biovest International
Phase 3
Unknown
629 enrolled